News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
555,706 Results
Type
Article (46868)
Company Profile (117)
Press Release (508710)
Multimedia
Podcasts (153)
Webinars (22)
Section
Business (145817)
Career Advice (2424)
Deals (28140)
Drug Delivery (152)
Drug Development (68584)
Employer Resources (159)
FDA (16040)
Job Trends (12078)
News (265775)
Policy (29929)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2331)
Academic (1)
Accelerated approval (45)
Adcomms (37)
Allergies (152)
Alliances (36143)
ALS (185)
Alzheimer's disease (1781)
Antibody-drug conjugate (ADC) (369)
Approvals (16220)
Artificial intelligence (566)
Autoimmune disease (222)
Automation (40)
Bankruptcy (313)
Best Places to Work (9193)
BIOSECURE Act (23)
Biosimilars (202)
Biotechnology (70)
Bladder cancer (177)
Brain cancer (60)
Breast cancer (630)
Cancer (5012)
Cardiovascular disease (453)
Career advice (2056)
Career pathing (43)
CAR-T (273)
CDC (71)
Celiac Disease (1)
Cell therapy (775)
Cervical cancer (40)
Clinical research (59477)
Collaboration (1650)
Company closure (6)
Compensation (1271)
Complete response letters (90)
COVID-19 (2732)
CRISPR (96)
C-suite (902)
Cystic fibrosis (146)
Data (6577)
Decentralized trials (3)
Denatured (33)
Depression (168)
Dermatology (57)
Diabetes (522)
Diagnostics (5660)
Digital health (41)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (257)
Drug pricing (232)
Drug shortages (33)
Duchenne muscular dystrophy (275)
Earnings (63159)
Editorial (71)
Employer branding (20)
Employer resources (142)
Events (82869)
Executive appointments (945)
FDA (19406)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (26)
Funding (1392)
Gene editing (209)
Generative AI (51)
Gene therapy (668)
GLP-1 (1119)
Government (4236)
Grass and pollen (8)
Guidances (387)
Healthcare (14919)
HIV (73)
Huntington's disease (56)
IgA nephropathy (94)
Immunology and inflammation (313)
Immuno-oncology (80)
Indications (145)
Infectious disease (3031)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (258)
Interviews (454)
IPO (14141)
IRA (58)
Job creations (3175)
Job search strategy (1674)
JPM (69)
Kidney cancer (19)
Labor market (91)
Layoffs (626)
Leadership (44)
Legal (7021)
Liver cancer (97)
Longevity (23)
Lung cancer (661)
Lymphoma (383)
Machine learning (48)
Management (52)
Manufacturing (849)
MASH (183)
Medical device (11651)
Medtech (11717)
Mergers & acquisitions (15066)
Metabolic disorders (1457)
mRNA (201)
Multiple sclerosis (156)
NASH (23)
Neurodegenerative disease (388)
Neuropsychiatric disorders (110)
Neuroscience (3144)
Neurotech (2)
NextGen: Class of 2026 (5000)
Non-profit (3203)
Now hiring (33)
Obesity (732)
Opinion (294)
Ovarian cancer (169)
Pain (213)
Pancreatic cancer (246)
Parkinson's disease (333)
Partnered (26)
Patents (528)
Patient recruitment (558)
Peanut (57)
People (44516)
Pharmaceutical (33)
Pharmacy benefit managers (34)
Phase 1 (17849)
Phase 2 (25746)
Phase 3 (21073)
Pipeline (6723)
Policy (359)
Postmarket research (2207)
Preclinical (7219)
Press Release (28)
Prostate cancer (275)
Psychedelics (58)
Radiopharmaceuticals (268)
Rare diseases (1041)
Real estate (4304)
Recruiting (65)
Regulatory (23651)
Reports (43)
Research institute (2132)
Resumes & cover letters (405)
Rett syndrome (32)
RNA editing (17)
RSV (80)
Schizophrenia (169)
Series A (240)
Series B (183)
Service/supplier (8)
Sickle cell disease (106)
Special edition (27)
Spinal muscular atrophy (147)
Sponsored (50)
Startups (2798)
State (1)
Stomach cancer (21)
Supply chain (117)
Tariffs (102)
The Weekly (118)
Vaccines (1146)
Venture capital (106)
Weight loss (513)
Women's health (92)
Worklife (23)
Date
Last 7 days (581)
Last 30 days (2356)
Last 365 days (28148)
2026 (7495)
2025 (28394)
2024 (31396)
2023 (34982)
2022 (45058)
2021 (48498)
2020 (45510)
2019 (36209)
2018 (27395)
2017 (27803)
2016 (25803)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (687)
Alabama (72)
Alaska (6)
Arizona (252)
Arkansas (11)
Asia (32551)
Australia (5704)
California (11325)
Canada (2691)
China (1017)
Colorado (446)
Connecticut (501)
Delaware (330)
Europe (79673)
Florida (1732)
Georgia (352)
Hawaii (4)
Idaho (40)
Illinois (827)
India (65)
Indiana (458)
Iowa (22)
Japan (461)
Kansas (108)
Kentucky (32)
Louisiana (30)
Maine (74)
Maryland (1382)
Massachusetts (8184)
Michigan (284)
Minnesota (595)
Mississippi (5)
Missouri (127)
Montana (13)
Nebraska (23)
Nevada (123)
New Hampshire (63)
New Jersey (3068)
New Mexico (15)
New York (2947)
North Carolina (1444)
North Dakota (7)
Northern California (5687)
Ohio (309)
Oklahoma (17)
Oregon (34)
Pennsylvania (2177)
Puerto Rico (20)
Rhode Island (33)
South America (1046)
South Carolina (73)
South Dakota (1)
Southern California (4445)
Tennessee (169)
Texas (1718)
United States (39591)
Utah (285)
Virginia (269)
Washington D.C. (73)
Washington State (882)
West Virginia (4)
Wisconsin (117)
Wyoming (1)
555,706 Results for "lipha s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while Rhythm’s Phase 3 basket trial fails to find the beat; Eli Lilly warns of potential safety risks of taking compounded tirzepatide, and Novo Nordisk is hit with an FDA warning letter regarding adverse events potentially linked to Ozempic.
March 18, 2026
·
1 min read
·
Heather McKenzie
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.
March 9, 2026
·
2 min read
·
Tristan Manalac
Approvals
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod
With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.
March 19, 2026
·
2 min read
·
Heather McKenzie
Podcast
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a new psoriasis drug. Plus, Aurinia Pharmaceuticals gets a new C-suite, FDA releases draft guidance on non-animal models and the CDC’s vaccine advisory committee is not being disbanded after all.
March 25, 2026
·
1 min read
·
Heather McKenzie
Job Trends
Beyond the Cornfields, Indiana’s Life Sciences Industry Grows Tall
With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its mark. The president and CEO of the Indiana Life Sciences Association discusses the sector’s upside, challenges and where it’s headed in the future.
March 26, 2026
·
5 min read
·
Angela Gabriel
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under probe for allegedly fostering a toxic workplace; Sarepta CEO Doug Ingram is stepping down after several years of tumult at the top of the muscular dystrophy–focused company; and Eli Lilly again tops Novo Nordisk in a weight loss trial.
March 4, 2026
·
1 min read
·
Heather McKenzie
Legal
Kennedy’s Vaccine Policy Overhaul Stymied by Federal Judge
A Massachusetts judge called Kennedy’s efforts to reform the CDC’s vaccines advisory panel a “procedural failure,” adding that the new committee members do not “comport with governing law.”
March 17, 2026
·
3 min read
·
Tristan Manalac
Regulatory
Disc’s FDA Rejection Raises Questions About Commissioner’s Vouchers
FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.
February 18, 2026
·
4 min read
·
Dan Samorodnitsky
Weight loss
Roche, Zealand’s Amylin Weight Loss Drug Fails To Clear Lilly’s Bar
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.
March 6, 2026
·
3 min read
·
Tristan Manalac
1 of 55,571
Next